Home
June 2008 July 2008 August 2008
Su Mo Tu We Th Fr Sa
Week 27 1 2 3 4 5
Week 28 6 7 8 9 10 11 12
Week 29 13 14 15 16 17 18 19
Week 30 20 21 22 23 24 25 26
Week 31 27 28 29 30 31

Tolterodine Extended Release Attenuates Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia - Abstract Show Comments PDF Print E-mail
  
Wednesday, 07 May 2008

Department of Urology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

In this open label, prospective study we determined the efficacy and tolerability of tolterodine extended release (ER) in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in whom previous alpha-blocker therapy had failed.

A total of 43 consecutive men with BPH and LUTS in whom a mean of 5.7 months of alpha-blocker therapy had failed due to adverse events (11) or a lack of efficacy (32) received tolterodine ER (4 mg daily) for 6 months. Primary efficacy end points were American Urological Association symptom score, and mean daytime and nighttime micturition frequency. Secondary end points were the peak urinary flow rate, post-void residual volume, the incidence of urinary retention, total score on the erectile function domain of the International Index of Erectile Function and adverse events.

A total of 39 men (91%) with a mean age of 61 years completed the 6-month trial. Mean 24-hour micturition frequency decreased from 9.8 to 6.3 voids and nocturia decreased from 4.1 to 2.9 episodes nightly. Significant changes in mean American Urological Association symptom scores (-6.1), the peak urinary flow rate (1.9 ml per second) and post-void residual volume (-22 ml) were also observed. Of the men 27 (63%) were potent at baseline and 29 (67%) were potent after 6 months of tolterodine ER treatment. Mean International Index of Erectile Function erectile function domain scores increased (6.9). Four men (9%) discontinued therapy because of intolerable dry mouth. There were no reports of urinary retention.

Treatment with tolterodine ER in men with BPH and LUTS may be a reasonable therapeutic option as initial therapy or after failed treatment with alpha-blockers.

Written by
Kaplan SA, Walmsley K, Te AE.

Reference
J Urol. 2008 May;179(5 Suppl):S82-5.
doi:10.1016/j.juro.2008.03.142

PubMed Abstract
PMID:18405763

UroToday.com BPH and Male LUTS Section

 

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >